-
Food for thought Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-12-19 Talha Burki
No Abstract
-
Bariatric surgery in children with obesity and type 2 diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-12-19 Ashish P Desai, Meghna S Vaghani, Li F Chan
No Abstract
-
Single-cell RNA sequencing identifies endothelial-derived HBEGF as promoting pancreatic beta cell proliferation in mice via the EGFR–Kmt5a–H4K20me pathway Diabetol. (IF 8.4) Pub Date : 2024-12-19 Fengling Lai, Kaixin Zhou, Yingjie Ma, Hao Lv, Weilin Wang, Rundong Wang, Tao Xu, Rong Huang
Aims/hypothesis Pancreatic beta cell mass is dynamically regulated in response to increased physiological and pathological demands. Understanding the mechanisms that control physiological beta cell proliferation could provide valuable insights into novel therapeutic approaches to diabetes. Here, we aimed to analyse the intracellular and extracellular signalling pathways involved in regulating the physiological
-
Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes Diabetol. (IF 8.4) Pub Date : 2024-12-19 Melanie R. Shapiro, Erin M. Tallon, Matthew E. Brown, Amanda L. Posgai, Mark A. Clements, Todd M. Brusko
Progress in developing therapies for the maintenance of endogenous insulin secretion in, or the prevention of, type 1 diabetes has been hindered by limited animal models, the length and cost of clinical trials, difficulties in identifying individuals who will progress faster to a clinical diagnosis of type 1 diabetes, and heterogeneous clinical responses in intervention trials. Classic placebo-controlled
-
Bereavement and type 1 diabetes in childhood: a register-based cohort study in Sweden Diabetol. (IF 8.4) Pub Date : 2024-12-19 Mona-Lisa Wernroth, Beatrice Kennedy, Katja Fall, Diem Nguyen, Awad I. Smew, Per-Ola Carlsson, Bodil Svennblad, Catarina Almqvist, Tove Fall
Aims/hypothesis The potential impact of childhood bereavement—a severe psychological stressor—on childhood type 1 diabetes development remains unclear. Here, we aimed to bridge this knowledge gap and assess whether bereavement characteristics influenced any impact. Methods We conducted a register-based cohort study encompassing 3,598,159 children born in Sweden between 1987 and 2020. Childhood bereavement
-
Limitations in Achieving Glycemic Targets From CGM Data and Persistence of Severe Hypoglycemia in Adults With Type 1 Diabetes Regardless of Insulin Delivery Method Diabetes Care (IF 14.8) Pub Date : 2024-12-19 Lori M. Laffel, Jennifer L. Sherr, Jingwen Liu, Wendy A. Wolf, Jeoffrey Bispham, Katherine S. Chapman, Daniel Finan, Lina Titievsky, Tina Liu, Kaitlin Hagan, Jason Gaglia, Keval Chandarana, Jeremy Pettus, Richard Bergenstal
OBJECTIVE We captured continuous glucose monitoring (CGM) metrics from a large online survey of adults with type 1 diabetes to determine how glycemic outcomes varied by insulin delivery form. RESEARCH DESIGN AND METHODS Adults with type 1 diabetes from the T1D Exchange Registry/online communities completed the survey and contributed retrospective CGM data for up to 1 year. Self-reported glycemic outcomes
-
Barriers to care for refugees and migrants with diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-12-17 Kiran Jobanputra, Gabriel Fabreau, Éimhín Ansbro
No Abstract
-
Gain of pancreatic beta cell-specific SCD1 improves glucose homeostasis by maintaining functional beta cell mass under metabolic stress Diabetol. (IF 8.4) Pub Date : 2024-12-18 Wenyue Yin, Suyun Zou, Min Sha, Liangjun Sun, Haoqiang Gong, Can Xiong, Xinyue Huang, Jianan Wang, Yuhan Zhang, Xirui Li, Jin Liang, Xiaoai Chang, Shusen Wang, Dongming Su, Wanhua Guo, Yaqin Zhang, Tijun Wu, Fang Chen
Aims/hypothesis The key pancreatic beta cell transcription factor v-maf musculoaponeurotic fibrosarcoma oncogene homologue A (MafA) is critical for the maintenance of mature beta cell function and phenotype. The expression levels and/or activities of MafA are reduced when beta cells are chronically exposed to diabetogenic stress, such as hyperglycaemia (i.e. glucotoxicity). Interventional targets and
-
Dose-related effects of intraduodenal quinine on plasma glucose, glucoregulatory hormones and gastric emptying of a nutrient drink, and energy intake, in men with type 2 diabetes: a double-blind, randomised, crossover study Diabetol. (IF 8.4) Pub Date : 2024-12-18 Vida Bitarafan, Javad Anjom-Shoae, Peyman Rezaie, Penelope C. E. Fitzgerald, Kylie Lange, Michael Horowitz, Christine Feinle-Bisset
Aims/hypothesis Quinine, when administered intraduodenally to activate bitter-taste receptors, in a dose of 600 mg, stimulates glucagon-like peptide-1 (GLP-1) and insulin, slows gastric emptying and lowers postprandial glucose in healthy people, with consequent implications for the management of type 2 diabetes; the effect of quinine on energy intake is uncertain. We have investigated the dose-related
-
Glycemic Management and Individualized Diabetes Care in Dialysis-Dependent Kidney Failure Diabetes Care (IF 14.8) Pub Date : 2024-12-18 Klara R. Klein, Ildiko Lingvay, Katherine R. Tuttle, Jennifer E. Flythe
Of the nearly 600,000 people in the U.S. who receive dialysis for chronic kidney failure, >60% have diabetes. People receiving dialysis who have diabetes have worse overall and cardiovascular survival rates than those without diabetes. Diabetes care in the dialysis setting is complicated by kidney failure–related factors that render extrapolation of glycated hemoglobin (HbA1c) targets to the dialysis
-
Technology for type 1 diabetes: what impact will it have? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-12-16 Maria E Craig
No Abstract
-
Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2–20 years) with type 1 diabetes: a population-based study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-12-16 Beate Karges, Joachim Rosenbauer, Anna Stahl-Pehe, Monika Flury, Torben Biester, Martin Tauschmann, Eggert Lilienthal, Johannes Hamann, Angela Galler, Reinhard W Holl
BackgroundThe effect of closed-loop insulin delivery on the risk of acute diabetes complications in people with type 1 diabetes is unclear. We investigated whether the rates of severe hypoglycaemia and diabetic ketoacidosis are lower with hybrid closed-loop insulin therapy compared with sensor-augmented (open-loop) pump therapy in a large cohort of young people. MethodsIn this population-based cohort
-
Identification of genetic factors of type 2 diabetes mellitus risk in South Asian populations Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-12-17 Olivia Tysoe
People of South Asian ancestry are more likely to develop type 2 diabetes mellitus (T2DM) at a younger age and lower BMI than people of European ancestry. The reasons for this fact are poorly understood, as the majority of genetic research on T2DM has been performed in white European populations. Now, a study in Nature Medicine has used partitioned polygenic risk scores (pPS) to uncover the genetic
-
From the perspective of a scientist with Cushing disease, what did not kill me made my science stronger Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-12-17 Yana Zavros
Research siloes slow the translation of scientific discovery to patient care and limit progress in improving treatments for Cushing disease to incremental advances. Facilitating collaborative efforts that study the complexity of pituitary neuroendocrine tumours would advance the development of targeted treatments for patients who experience a low quality of life for years owing to this rare and understudied
-
Exploring tryptophan metabolism in cardiometabolic diseases. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-12-17 Nirmala Mouttoulingam,Soraya Taleb
Tryptophan (Trp) metabolism is linked to health and disease, with indoleamine 2,3-dioxygenase 1 (IDO) being a key enzyme in its breakdown outside the liver. This process produces metabolites that influence metabolic and inflammatory responses. A distinctive feature of the gut is its involvement in three major Trp catabolic pathways: the IDO-driven kynurenine pathway, bacteria-produced indoles, and
-
Skeletal muscle adaptations and post-exertional malaise in long COVID. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-12-17 Braeden T Charlton,Richie P Goulding,Richard T Jaspers,Brent Appelman,Michèle van Vugt,Rob C I Wüst
When acute SARS-CoV-2 infections cause symptoms that persist longer than 3 months, this condition is termed long COVID. Symptoms experienced by patients often include myalgia, fatigue, brain fog, cognitive impairments, and post-exertional malaise (PEM), which is the worsening of symptoms following mental or physical exertion. There is little consensus on the pathophysiology of exercise-induced PEM
-
Inter-organ communication is a critical machinery to regulate metabolism and aging. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-12-17 Kyohei Tokizane,Shin-Ichiro Imai
Inter-organ communication (IOC) is a complex mechanism involved in maintaining metabolic homeostasis and healthy aging. Dysregulation of distinct forms of IOC is linked to metabolic derangements and age-related pathologies, implicating these processes as a potential target for therapeutic intervention to promote healthy aging. In this review, we delve into IOC mediated by hormonal signaling, circulating
-
Publisher Correction: Growth hormone-releasing hormone and its analogues in health and disease Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-12-16 Riccarda Granata, Sheila Leone, Xianyang Zhang, Iacopo Gesmundo, Charlotte Steenblock, Renzhi Cai, Wei Sha, Ezio Ghigo, Joshua M. Hare, Stefan R. Bornstein, Andrew V. Schally
Correction to: Nature Reviews Endocrinology https://doi.org/10.1038/s41574-024-01052-1, published online 13 November 2024.
-
Effect of Community-Based Integrated Care for Patients With Diabetes and Depression (CIC-PDD) in China: A Pragmatic Cluster-Randomized Trial Diabetes Care (IF 14.8) Pub Date : 2024-12-16 Yanshang Wang, Dan Guo, Yiqi Xia, Mingzheng Hu, Ming Wang, Qianqian Yu, Zhansheng Li, Xiaoyi Zhang, Ruoxi Ding, Miaomiao Zhao, Zhenyu Shi, Dawei Zhu, Ping He
OBJECTIVE To develop a care model for patients with both diabetes and depression and assess the model’s effectiveness. RESEARCH DESIGN AND METHODS In this pragmatic cluster randomized trial, we allocated eight community health centers into two groups: the enhanced usual care group and the intervention group. A comprehensive care plan was developed for the intervention group based on the integrated
-
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-12-13 Norbert Stefan, Hannele Yki-Järvinen, Brent A Neuschwander-Tetri
The global epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide. People with MASLD can progress to cirrhosis and hepatocellular carcinoma and are at increased risk of developing type 2 diabetes, cardiovascular disease, chronic kidney disease, and extrahepatic cancers. Most people with MASLD die from cardiac-related causes. This outcome is attributed to
-
Genetic variation in the RETN promoter, accompanied by latent sarcopenic obesity, led to insulin resistance in a Japanese cohort: the Toon Genome Study Diabetol. (IF 8.4) Pub Date : 2024-12-13 Yosuke Ikeda, Ryoichi Kawamura, Yasuharu Tabara, Koutatsu Maruyama, Daisuke Shiokawa, Misaki Takakado, Toshimi Hadate, Yasunori Takata, Jun Ohashi, Isao Saito, Yoshihiro Ogawa, Haruhiko Osawa
Aims/hypothesis Resistin, inducing insulin resistance, is elevated in the sera of individuals with the G-A haplotype at c.-420 C>G (rs1862513) and c.-358 G>A (rs3219175). This haplotype is associated with visceral obesity and low grip strength. To elucidate the hidden relationship between the G-A haplotype and insulin resistance, integration of specific phenotypes defined by body composition and 75
-
Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes Diabetol. (IF 8.4) Pub Date : 2024-12-13 Maria J. Redondo, David Cuthbertson, Andrea K. Steck, Kevan C. Herold, Richard Oram, Mark Atkinson, Todd M. Brusko, Hemang M. Parikh, Jeffrey P. Krischer, Suna Onengut-Gumuscu, Stephen S. Rich, Jay M. Sosenko
Aims/hypothesis Many studies of type 1 diabetes pathogenesis focus on individuals with high-risk HLA haplotypes. We tested the hypothesis that, among islet autoantibody-positive individuals, lacking HLA-DRB1*04-DQA1*03-DQB1*0302 (HLA-DR4-DQ8) and/or HLA-DRB1*0301-DQA1*0501-DQB1*0201 (HLA-DR3-DQ2) is associated with phenotypic differences, compared with those who have these high-risk HLA haplotypes
-
Intermittent and periodic fasting in the treatment of obesity and type 2 diabetes mellitus Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-12-13 Valter D. Longo
Several new clinical studies provide evidence for the potential of specific intermittent and periodic fasting interventions to decrease adiposity and HbA1c in patients with obesity and/or type 2 diabetes mellitus, while also reducing drug use, adverse effects and risk factors for other diseases.
-
Advances in appetite regulation by the arcuate nucleus Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-12-13 Cristina Garcia-Caceres
In 2024, new insights identified a cluster of leptin-targeted neurons and integrative networks that link sensory inputs (heat and food perception) with feeding centres and peripheral systems. Key findings revealed hypothalamic site-specific adaptive mechanisms, in which nutritional state-dependent remodelling of extracellular compounds and neuropeptide transmission calibrate appetite via the arcuate
-
The Microbiota and Evolution of Obesity. Endocr. Rev. (IF 22.0) Pub Date : 2024-12-13 Mario J A Saad,Andrey Santos
Obesity is a major global concern and is generally attributed to a combination of genetic and environmental factors. Several hypotheses have been proposed to explain the evolutionary origins of obesity epidemic, including thrifty and drifty genotypes, and changes in thermogenesis. Here, we put forward the hypothesis of metaflammation, which proposes that due to intense selection pressures exerted by
-
Elevated risk of infection in individuals with hyperinsulinaemic type 2 diabetes: a Danish 12 year cohort study Diabetol. (IF 8.4) Pub Date : 2024-12-11 Frederik P. B. Kristensen, Sidsel L. Domazet, Jens S. Nielsen, Jacob V. Stidsen, Kurt Højlund, Henning Beck-Nielsen, Peter Vestergaard, Niels Jessen, Michael H. Olsen, Torben Hansen, Charlotte Brøns, Allan Vaag, Henrik T. Sørensen, Reimar W. Thomsen
Aims/hypothesis A better understanding of the mechanisms underlying an elevated infection risk in individuals with type 2 diabetes is needed to guide risk stratification and prevention. We investigated the risk of infection in subgroups of individuals with type 2 diabetes according to indices of insulin sensitivity and beta cell function. Methods We classified 7265 individuals with recently diagnosed
-
The era of GLP-1 receptor agonists: costs versus benefits Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-12-12
No Abstract
-
Risk of Nephrolithiasis Associated With SGLT2 Inhibitors Versus DPP4 Inhibitors Among Patients With Type 2 Diabetes: A Target Trial Emulation Study Diabetes Care (IF 14.8) Pub Date : 2024-12-12 Anna Shin, Ju-Young Shin, Eun Ha Kang
OBJECTIVE We aim to compare the risk of nephrolithiasis among type 2 diabetes patients who initiated sodium-glucose cotransporter-2 inhibitors (SGLT2is) versus dipeptidyl-peptidase-4 inhibitors (DPP4is), individually within stone never- and ever-formers. RESEARCH DESIGN AND METHODS Using the 2010–2021 Korea National Health Insurance Service database, we conducted a population-based cohort study, comparing
-
Intracellular endothelial cell metabolism in vascular function and dysfunction. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-12-12 Kathryn M Citrin,Balkrishna Chaube,Carlos Fernández-Hernando,Yajaira Suárez
Endothelial cells (ECs) form the inner lining of blood vessels that is crucial for vascular function and homeostasis. They regulate vascular tone, oxidative stress, and permeability. Dysfunction leads to increased permeability, leukocyte adhesion, and thrombosis. ECs undergo metabolic changes in conditions such as wound healing, cancer, atherosclerosis, and diabetes, and can influence disease progression
-
Loss of β-cell KATP reduces Ca2+ sensitivity of insulin secretion and Trpm5 expression Diabetes (IF 6.2) Pub Date : 2024-12-12 Nathaniel W. York, Zihan Yan, Anna B. Osipovich, Abbie Tate, Sumit Patel, David W. Piston, Mark A. Magnuson, Maria S. Remedi, Colin G. Nichols
Loss-of-function (LOF) mutations in KATP channels cause hyperexcitability and insulin hypersecretion, resulting in congenital hyperinsulinism (CHI). Paradoxically, despite the initial insulin hypersecretion, many CHI cases, as well as KATP knockout (KO) animals, eventually ‘crossover’ to undersecretion and even diabetes. Here we confirm that Sur1 KO islets exhibit higher intracellular [Ca2+] ([Ca2+]i)
-
Sex differences in response to the endothelin receptor antagonist atrasentan in individuals with type 2 diabetes and chronic kidney disease: a post hoc analysis of the SONAR trial Diabetol. (IF 8.4) Pub Date : 2024-12-11 J. David Smeijer, Sieta T. de Vries, Donald E. Kohan, Fan Fan Hou, Hiddo J. L. Heerspink
Aims/hypothesis In the Study Of diabetic Nephropathy with AtRasentan (SONAR), the endothelin receptor antagonist (ERA) atrasentan slowed progression of chronic kidney disease (CKD) in individuals with type 2 diabetes. Pre-clinical research suggests sex-based differences in the endothelin system might influence the efficacy and safety of atrasentan. We therefore assessed the effects of atrasentan in
-
The Biology and Clinical Implications of PCSK7. Endocr. Rev. (IF 22.0) Pub Date : 2024-12-11 Vatsal Sachan,Delia Susan-Resiga,Kalista Lam,Nabil G Seidah
Discovered in 1996, PCSK7 is the seventh of the nine-membered proprotein convertase subtilisin-kexin (PCSK) family. This article reviews the various aspects of the multifaceted biology of PCSK7 and what makes it an exciting new target for metabolic dysfunction-associated steatotic liver disease (MASLD) affecting ∼30% of the population globally, dyslipidemia, cardiovascular disease (CVD), and likely
-
The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD) Diabetol. (IF 8.4) Pub Date : 2024-12-10 Othmar Moser, Dessi P. Zaharieva, Peter Adolfsson, Tadej Battelino, Richard M. Bracken, Bruce A. Buckingham, Thomas Danne, Elizabeth A. Davis, Klemen Dovč, Gregory P. Forlenza, Pieter Gillard, Sabine E. Hofer, Roman Hovorka, Peter G. Jacobs, Julia K. Mader, Chantal Mathieu, Kirsten Nørgaard, Nick S. Oliver, David N. O’Neal, John Pemberton, Rémi Rabasa-Lhoret, Jennifer L. Sherr, Harald Sourij, Martin
Regular physical activity and exercise (PA) are cornerstones of diabetes care for individuals with type 1 diabetes. In recent years, the availability of automated insulin delivery (AID) systems has improved the ability of people with type 1 diabetes to achieve the recommended glucose target ranges. PA provide additional health benefits but can cause glucose fluctuations, which challenges current AID
-
Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials Diabetol. (IF 8.4) Pub Date : 2024-12-10 Sieta T. de Vries, Michelle J. Pena, Sok Cin Tye, Sanne A. E. Peters, Daniël H. van Raalte, Clare Arnott, Adriaan A. Voors, Peter G. M. Mol, Petra Denig, Hiddo J. L. Heerspink
Aims/hypothesis Our aim was to assess sex differences in the efficacy of angiotensin receptor blockers (i.e. losartan and irbesartan) on kidney and cardiovascular outcomes in individuals with type 2 diabetes and diabetic kidney disease. Methods Data from the Angiotensin II Antagonist Losartan Study (RENAAL) and Irbesartan type II Diabetic Nephropathy Trial (IDNT) were used. The kidney outcome was time
-
The impact of the US election on diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-12-10 Irl B Hirsch, Desmond A Schatz
No Abstract
-
Surveying the landscape of emerging osteoanabolic therapies Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-12-09 Thomas H. Ambrosi
Established antiresorptive treatments for osteoporosis only slow down bone loss, and available osteoanabolic therapies — although more effective — have broad limitations. Recent insights into sex-specific systemic regulation of skeletal mass, an enhanced understanding of the cellular complexity of bone marrow and innovative options such as senolytics have fuelled the development of potentially transformative
-
Use of SGLT2i Versus DPP-4i as an Add-On Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes Diabetes Care (IF 14.8) Pub Date : 2024-12-09 Katherine E. Griffin, Kathryn Snyder, Amir H. Javid, Amber Hackstadt, Robert Greevy, Carlos G. Grijalva, Christianne L. Roumie
OBJECTIVE To compare the risk of composite peripheral artery disease (PAD) surgical outcome, including peripheral revascularization and amputation procedures, between new users of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and dipeptidyl peptidase 4 inhibitors (DPP-4is). RESEARCH DESIGN AND METHODS This retrospective cohort study of U.S. veterans age ≥18 years with diabetes who received care
-
Adipose tissue biology and effect of weight loss in women with lipedema Diabetes (IF 6.2) Pub Date : 2024-12-09 Vincenza Cifarelli, Gordon I. Smith, Silvia Gonzalez-Nieves, Dmitri Samovski, Hector H. Palacios, Jun Yoshino, Richard I. Stein, Anja Fuchs, Thomas F. Wright, Samuel Klein
Lipedema is a lipodystrophic disease that is typically characterized by a marked increase in lower-body subcutaneous adipose tissue that is purported to have increased inflammation and fibrosis, impaired microvascular/lymphatic circulation and to be resistant to reduction by weight loss therapy. However, these outcomes have not been adequately studied. We evaluated body composition, insulin sensitivity
-
Gain of function NOTCH3 variants cause familial partial lipodystrophy due to activation of senescence pathways Diabetes (IF 6.2) Pub Date : 2024-12-09 Abhimanyu Garg, Chao Xing, Anil K. Agarwal, Aundrea K. Westfall, Diana R. Tomchick, Xunzhi Zhang, Michelle Xing, Rebecca J. Brown
Despite elucidation of the molecular genetic basis of several lipodystrophy syndromes, molecular defects in some ultra-rare subtypes of familial lipodystrophies remain unidentified. We analyzed whole exome sequencing (WES) data of four affected and two unaffected females from an undiagnosed autosomal dominant familial partial lipodystrophy (FPL) pedigree and identified only one novel heterozygous variant
-
Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial Diabetes Care (IF 14.8) Pub Date : 2024-12-06 Patrizia Pasanisi, Andreina Oliverio, Ivan Baldassari, Eleonora Bruno, Elisabetta Venturelli, Manuela Bellegotti, Giuliana Gargano, Daniele Morelli, Antonio Bognanni, Marta Rigoni, Paola Muti, Franco Berrino
OBJECTIVE The Metformin and Dietary Restriction to Prevent Age-Related Morbid Events in People With Metabolic Syndrome (MeMeMe) trial tested whether 1,700 mg/day metformin (MET) with or without a Mediterranean diet (MedDiet) intervention could reduce the cumulative incidence of major noncommunicable diseases in people with metabolic syndrome. RESEARCH DESIGN AND METHODS A total of 1,442 participants
-
Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function Diabetol. (IF 8.4) Pub Date : 2024-12-05 Matthew E. Brown, Puchong Thirawatananond, Leeana D. Peters, Elizabeth J. Kern, Sonali Vijay, Lindsey K. Sachs, Amanda L. Posgai, Maigan A. Brusko, Melanie R. Shapiro, Clayton E. Mathews, Rhonda Bacher, Todd M. Brusko
Aims/hypothesis Immunotherapeutics targeting T cells are crucial for inhibiting autoimmune disease progression proximal to disease onset in type 1 diabetes. There is an outstanding need to augment the durability and effectiveness of T cell targeting therapies by directly restraining proinflammatory T cell subsets, while simultaneously augmenting regulatory T cell (Treg) activity. Here, we present a
-
Growth Hormone Action as a Target in Cancer: Significance, Mechanisms and Possible Therapies. Endocr. Rev. (IF 22.0) Pub Date : 2024-12-05 Reetobrata Basu,Cesar L Boguszewski,John J Kopchick
Growth hormone (GH) is a pituitary derived endocrine hormone required for normal post-natal growth and development. Hypo or hypersecretion of endocrine GH results in two pathologic conditions, namely GH deficiency (GHD) and acromegaly. Additionally, GH is also produced in non-pituitary and tumoral tissues where it acts rather as a cellular growth factor with an autocrine/paracrine mode of action. An
-
Can brain neurons change identity? Lessons from obesity. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-12-05 Jean Charles Nicolas,Thomas H Lee,Carmelo Quarta
It has long been thought that the functional identity of mammalian brain neurons is programmed during development and remains stable throughout adult life; however, certain populations of neurons continue to express active regulators of neuronal identity into adulthood. Prolonged exposure to diet-induced metabolic stress induces features of neuronal identity modification in adult mice, and maladaptive
-
Advances in basic biology and translation in islet research Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-12-04 Carmella Evans-Molina
Advances in islet cell biology over the past few years highlight a fundamental role for intra-islet endocrine cell interactions and δ-cells in the regulation of glycaemia. New insights into how cellular heterogeneity and individual-level heterogeneity effect hormone secretion have also emerged.
-
Advances in cardiometabolic outcomes in polycystic ovary syndrome Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-12-04 Lisa J. Moran
The year 2024 brought continuing research in the crucial field of adiposity-related health and polycystic ovary syndrome (PCOS). Although PCOS is considered a heterogeneous condition with regards to diagnostic criteria, complications and management, current research is advancing our understanding of the presentation and metabolic features of PCOS, as well as the benefits of lifestyle management.
-
Diabetes Body Project: Acute Effects of an Eating Disorder Prevention Program for Young Women With Type 1 Diabetes. A Multinational Randomized Controlled Trial Diabetes Care (IF 14.8) Pub Date : 2024-12-04 Mareille H.C.L. Hennekes, Severina Haugvik, Maartje de Wit, Elena Toschi, Christopher D. Desjardins, Torild Skrivarhaug, Knut Dahl-Jørgensen, Eric Stice, Line Wisting
OBJECTIVE Young women with type 1 diabetes are at risk to develop eating disorders (ED). We evaluated a novel ED prevention program in a multinational randomized controlled trial. RESEARCH DESIGN AND METHODS Women (14–35 years old) with type 1 diabetes were randomized to virtual Diabetes Body Project groups or educational control. Outcomes were assessed at pretest and posttest (1–2 weeks after intervention)
-
Rewiring of the glymphatic landscape in metabolic disorders. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-12-04 Bandy Chen,David Meseguer,Stephanie Lenck,Jean-Leon Thomas,Marc Schneeberger
The incorporation of the glymphatic clearance system in the study of brain physiology aids in the advancement of innovative diagnostic and treatment strategies for neurological disorders. Exploring the glymphatic system across (from) neurological and (to) metabolic diseases may provide a better link between obesity and neurological disorders. Recent studies indicate the role of metabolic dysfunction
-
β-Cell Secretory Capacity Predicts Metabolic Outcomes over 6 Years following Human Islet Transplantation Diabetes (IF 6.2) Pub Date : 2024-12-04 Anneliese J. Flatt, Austin M. Matus, Robert J. Gallop, Eileen Markmann, Cornelia Dalton-Bakes, Amy J. Peleckis, Chengyang Liu, Ali Naji, Michael R. Rickels
Transplanted islet functional β-cell mass is measured by the β-cell secretory capacity derived from the acute insulin response to glucose-potentiated arginine (AIRpot), however, data are limited beyond one-year post-transplant for individuals with type 1 diabetes. We evaluated changes in β-cell secretory capacity in a single-center longitudinal analysis and examined relationships with measures of islet
-
Memory of obesity stored in adipocytes Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-12-03 Claire Greenhill
In humans, weight loss as a result of lifestyle interventions, pharmacotherapy or bariatric surgery is often followed by weight regain. It is thought that cells retain an obesogenic memory that predisposes the body to return to the previous level of adiposity; however, the mechanisms that underlie this effect have been unclear. A new study has now demonstrated that adipocytes in humans and mice retain
-
Dysglycaemia definitions and progression to clinical type 1 diabetes in children with multiple islet autoantibodies Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-12-03 Sandra Hummel, Melanie Koeger, Ezio Bonifacio, Anette-Gabriele Ziegler
No Abstract
-
Genetic Discovery and Risk Prediction for Type 1 Diabetes in Individuals Without High-Risk HLA-DR3/DR4 Haplotypes Diabetes Care (IF 14.8) Pub Date : 2024-12-03 Carolyn McGrail, Joshua Chiou, Ruth Egamal, Amber M. Luckett, Richard A. Oram, Paola Benaglio, Kyle J. Gaulton
OBJECTIVE More than 10% of patients with type 1 diabetes (T1D) do not have high-risk HLA-DR3 or -DR4 haplotypes with distinct clinical features, such as later onset and reduced insulin dependence. We aimed to identify genetic drivers of T1D in the absence of DR3/DR4 and improve prediction of T1D risk in these individuals. RESEARCH DESIGN AND METHODS We performed T1D association and fine-mapping analyses
-
A critique of measurement of defective insulin secretion and insulin sensitivity as a precision approach to gestational diabetes Diabetol. (IF 8.4) Pub Date : 2024-12-02 Danielle L. Jones, Laura C. Kusinski, Clare Gillies, Claire L. Meek
Aims/hypothesis Precision medicine approaches to gestational diabetes mellitus (GDM) have categorised patients according to disease pathophysiology (insulin resistance, insulin insufficiency or both), and demonstrated associations with clinical outcomes. We aimed to assess whether using enhanced processing to determine indices of insulin secretion and sensitivity is analytically robust, reproducible
-
The effect of vitamin D3 supplementation on the incidence of type 2 diabetes in healthy older adults not at high risk for diabetes (FIND): a randomised controlled trial Diabetol. (IF 8.4) Pub Date : 2024-12-02 Jyrki K. Virtanen, Sari Hantunen, Niko Kallio, Christel Lamberg-Allardt, JoAnn E. Manson, Tarja Nurmi, Jussi Pihlajamäki, Matti Uusitupa, Ari Voutilainen, Tomi-Pekka Tuomainen
Aims/hypothesis Vitamin D insufficiency is associated with an elevated risk of type 2 diabetes, but evidence from randomised trials on the benefits of vitamin D supplementation is limited, especially for average-risk populations. The Finnish Vitamin D Trial (FIND) investigated the effects of vitamin D3 supplementation at two different doses on the incidence of type 2 diabetes in a generally healthy
-
Metabolomics profiling in multi-ancestral individuals with type 2 diabetes in Singapore identified metabolites associated with renal function decline Diabetol. (IF 8.4) Pub Date : 2024-12-02 Yuqing Chen, Federico Torta, Hiromi W. L. Koh, Peter I. Benke, Resham L. Gurung, Jian-Jun Liu, Keven Ang, Yi-Ming Shao, Gek Cher Chan, Jason Chon-Jun Choo, Jianhong Ching, Jean-Paul Kovalik, Tosha Kalhan, Rajkumar Dorajoo, Chiea Chuen Khor, Yun Li, Wern Ee Tang, Darren E. J. Seah, Charumathi Sabanayagam, Radoslaw M. Sobota, Kavita Venkataraman, Thomas Coffman, Markus R. Wenk, Xueling Sim, Su-Chi Lim
Aims/hypothesis This study aims to explore the association between plasma metabolites and chronic kidney disease progression in individuals with type 2 diabetes. Methods We performed a comprehensive metabolomic analysis in a prospective cohort study of 5144 multi-ancestral individuals with type 2 diabetes in Singapore, using eGFR slope as the primary outcome of kidney function decline. In addition
-
Evidence on the effectiveness and equity of population-based policies to reduce the burden of type 2 diabetes: a narrative review Diabetol. (IF 8.4) Pub Date : 2024-12-02 Joreintje D. Mackenbach, Josine M. Stuber, Joline W. J. Beulens
There is increasing evidence for the effectiveness of population-based policies to reduce the burden of type 2 diabetes. Yet, there are concerns about the equity effects of some policies, whereby socioeconomically disadvantaged populations are not reached or are adversely affected. There is a lack of knowledge on the effectiveness and equity of policies that are both population based (i.e. targeting
-
Continuous Glucose Monitor Accuracy for Diabetes Management in Hospitalized Children Diabetes Care (IF 14.8) Pub Date : 2024-12-02 Neha Garg, Kamryn Lewis, Perrin C. White, Soumya Adhikari
OBJECTIVE The adoption of continuous glucose monitors (CGMs) in inpatient settings in the pediatric population has been slow because of a scarcity of data on their reliability in hospitalized children. RESEARCH DESIGN AND METHODS We retrospectively reviewed the accuracy of the Dexcom G6 CGM system in pediatric patients with diabetes admitted to our academic children’s hospital from March 2018 to September
-
Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from the American Diabetes Association Diabetes Care (IF 14.8) Pub Date : 2024-12-02 Joshua J. Neumiller, Mandeep Bajaj, Raveendhara R. Bannuru, Rozalina G. McCoy, Elizabeth J. Pekas, Alissa R. Segal, Nuha A. ElSayed
The use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA (GIP/GLP-1 RA) classes has increased substantially over the past several years for treating type 2 diabetes and obesity. Increased demand for these pharmacotherapies has resulted in temporary product shortages for both GLP-1 RA and dual GIP/GLP-1 RA medications. These
-
Plasma proteomic signatures of adiposity are associated with cardiovascular risk factors and type 2 diabetes risk in a multi-ethnic Asian population. Diabetes (IF 6.2) Pub Date : 2024-12-02 Charlie G.Y. Lim, Bige Ozkan, Yujian Liang, Jingsha Chen, Jiali Yao, Nang Ei Ei Khaing, Mary R. Rooney, Chiadi E. Ndumele, E Shyong Tai, Josef Coresh, Xueling Sim, Rob M. van Dam
The biomarkers connecting obesity and cardiometabolic diseases are not fully understood. We aimed to (i) evaluate the associations between body mass index (BMI), waist circumference (WC), and ∼5,000 plasma proteins (SomaScan v4), (ii) identify protein signatures of BMI and WC, and (iii) evaluate the associations between the protein signatures and cardiometabolic health including metabolically unhealthy
-
Blocking adipocyte YY1 decouples thermogenesis from beneficial metabolism by promoting spermidine production Diabetes (IF 6.2) Pub Date : 2024-12-02 Chen Qiu, Yu Lu, Suyang Wu, Wenli Guo, Jiahao Ni, Jiyuan Song, Zichao Liu, Xiaoai Chang, Kai Wang, Peng Sun, Qian Zhang, Shufang Yang, Kai Li
The accumulation of mitochondria in thermogenic adipose tissue (i.e., brown and beige fat) increases energy expenditure, which can aid in alleviating obesity and metabolic disorders. However, recent studies have shown that knocking out key proteins required to maintain mitochondrial function inhibits the energy expenditure in thermogenic fat, and yet the knockout mice are unexpectedly protected from